explore -WSS

explore

author：hotspot 2025-09-02 11:41:05 - browse：9757

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Companies helping big Covid

explore

WSS

A Greenpeace activist is fined for crash

Caribou posts encouraging results on off

Delta passengers in Vegas fall sick while waiting on flight in triple

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Delta passengers in Vegas fall sick while waiting on flight in triple

United colonoscopy coverage change 'may cost lives,' doctors say

Are infertility treatments 'essential' during the Covid

Cancer drug shortages should be causing more outrage

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

Moonlake's readout produced a cash windfall. Risks remain

Grail's uphill battle for Medicare to cover its cancer screening test

Hepatitis C has a cure — but many Americans still lack access to it

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

explore

Sickle cell gene therapy cures need to be accessible in Africa

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

EU fines Illumina $475 million over Grail acquisition

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

The stock market has soared this year, but will it last? Experts weigh in

focus

focus

explore

focus